Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial

Three-year follow-up results from the phase 2 PERMEATE trial—presented during the 2023 ASCO Annual Meeting—showed that irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib plus capecitabine may provide long-term survival benefit in patients with metastatic HER2-positive breast cancer and brain metastases, particularly in radiotherapy-naïve patients.